Abstract
Purpose
To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case–control study nested in the Prostate Cancer Prevention Trial (PCPT).
Methods
Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies.
Results
No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89–1.45).
Conclusions
Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sutcliffe S (2010) Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol 6:1289–1311
Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170:998–1002
Sfanos KS, Sauvageot J, Fedor HL et al (2008) A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 68:306–320
Boldogh I, Baskar JF, Mar EC, Huang ES (1983) Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. J Natl Cancer Inst 70:819–826
Geder L, Sanford EJ, Rohner TJ, Rapp F (1977) Cytomegalovirus and cancer of the prostate: in vitro transformation of human cells. Cancer Treat Rep 61:139–146
Rouphael NG, Laskar SR, Smith A, Lyon GM (2011) Cytomegalovirus prostatitis in a heart transplant recipient. Am J Transpl 11:1330–1333
De Marzo AM, Platz EA, Sutcliffe S et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269
Sanford EJ, Geder L, Laychock A, Rohner TJ Jr, Rapp F (1977) Evidence for the association of cytomegalovirus with carcinoma of the prostate. J Urol 118:789–792
Laychock AM, Geder L, Sanford EJ, Rapp F (1978) Immune response of prostatic cancer patients to cytomegalovirus-infected and -transformed human cells. Cancer 42:1766–1771
Berrington de Gonzalez A, Urban MI, Sitas F et al (2006) Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. Infect Agent Cancer 1:2
Bergh J, Marklund I, Gustavsson C et al (2007) No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 96:137–139
Huang WY, Hayes R, Pfeiffer R et al (2008) Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 17:2374–2381
Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS et al (2010) Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 10:326
Hrbacek J, Urban M, Hamsikova E et al (2011) Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer 11:53
Goodman PJ, Tangen CM, Crowley JJ et al (2004) Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 25:203–222
Zhu J, Davidson M, Leinonen M et al (2006) Prevalence and persistence of antibodies to herpes viruses, Chlamydia pneumoniae and Helicobacter pylori in Alaskan Eskimos: the GOCADAN study. Clin Microbiol Infect 12:118–122
Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180:702–707
Staras SA, Dollard SC, Radford KW et al (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 43:1143–1151
Kristal AR, Arnold KB, Schenk JM et al (2008) Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 167:925–934
Sutcliffe S, Zenilman JM, Ghanem KG et al (2006) Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 175:1937–1942
Mandel JS, Schuman LM (1987) Sexual factors and prostatic cancer: results from a case-control study. J Gerontol 42:259–264
Acknowledgments
We thank the technicians from the PCPT Pathology and Genotyping Core directed by M. Scott Lucia for their efforts in providing serum specimens for testing, the Baltimore City Health Department (Dr. Emily J. Erbelding, Vincent Marsiglia, and Sarah Norman) for generous provision of quality control serum specimens, Patricia Agreda for CMV antibody testing, Ratna Pakpahan for preparation of CMV antibody data, and Dr. Catherine M. Tangen for general statistical discussions. This project was funded by research grants P01 CA108964 (Biology of the PCPT), P30 CA054174, and U01 CA37429 from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, and the Barnes-Jewish Hospital Foundation. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sutcliffe, S., Till, C., Gaydos, C.A. et al. Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes Control 23, 1511–1518 (2012). https://doi.org/10.1007/s10552-012-0028-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-012-0028-5